GlaxoSmithKline (GSK) Deal History & Licensing Activity
GlaxoSmithKline (GSK) is a large pharma headquartered in GB. Over the past three years, GlaxoSmithKline (GSK) has been involved in 2 licensing and acquisition transactions, with a primary focus on ADC (2 deals). The company currently has 4 active clinical trials, primarily in Infectious.
Deals (12mo)
2
Active Trials
4
Top Modality
ADC
Focus Area
Infectious
GlaxoSmithKline (GSK) Recent Deal Activity
Licensing, acquisition, and partnership transactions involving GlaxoSmithKline (GSK) in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| HMPL-A830 | HUTCHMED (China) Limited | ADC | Preclinical | license | Sep 3, 2026 |
| siRNA candidates (two programs) | Frontier Biotechnologies (前沿生物药业（南京）股份有限公司) | Oligonucleotides | Preclinical | license | Mar 18, 2026 |
GlaxoSmithKline (GSK) Pipeline Focus
Therapeutic areas and modalities where GlaxoSmithKline (GSK) is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
GlaxoSmithKline (GSK) Clinical Pipeline
GlaxoSmithKline (GSK) has 4 active clinical trials across 2 development phases.
1
Phase 1/2
3
Phase 3
See How Your Asset Matches GlaxoSmithKline (GSK)'s Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Infectious assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Oncology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for oncology
ADC Benchmarks
Upfront, milestone, and royalty benchmarks for adc deals
Oligonucleotides Benchmarks
Upfront, milestone, and royalty benchmarks for oligonucleotides deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 700+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About GlaxoSmithKline (GSK) Licensing & Deal Activity
GlaxoSmithKline (GSK) is a large pharma company based in GB that has been actively engaged in licensing transactions across the biopharma landscape. With 2 deals over the past three years, GlaxoSmithKline (GSK) ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for GlaxoSmithKline (GSK) include Infectious (3 deals and trials), Oncology (2 deals and trials), and Other (2 deals and trials). In terms of modality, GlaxoSmithKline (GSK) has shown particular interest in adc, oligonucleotides.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for GlaxoSmithKline (GSK) and 700+ other biopharma companies. Use our Solidus to benchmark your asset against GlaxoSmithKline (GSK)'s historical deal terms, or explore all company profiles to find the best partner match for your pipeline.